TITLE

OUTCOME PREDICTION FOLLOWING NEOADJUVANT ECF CHEMOTHERAPY FOR OESOPHAGO-GASTRIC CANCER

AUTHOR(S)
Forshaw, M.; Gossage, J.; Strauss, D.; Chrystal, K.; Harper, P.; Mason, R.
PUB. DATE
April 2004
SOURCE
Gut;Apr2004 Supplement 3, Vol. 53, pA27
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Neoadjuvant chemotherapy is increasingly being used to downstage locally advanced oesophago-gastric cancer. Predicting response to treatment is important in order to target surgery to those individuals who would derive the maximum benefit. The aim of this study was to assess whether radiological or symptomatic parameters could aid surgical decision making. It was found that both biological and radiological responses to neoadjuvant ECF chemotherapy should play an important role in surgical decision making. These parameters should be carefully measured and assessed in future prospective trials.
ACCESSION #
13218919

 

Related Articles

  • Minimally Invasive Esophagectomy/Gastroesophagectomy for Cancer. Is it Safe in Nepalese Context? Thakur, Binay; Li Hui; Devkota, Mukti; Chen Xin; Lama, Robin // Journal of Cancer Science & Therapy;2012, Vol. 4 Issue 4, p102 

    Background: Minimally invasive approach for cancer of esophagus and gastroesophageal junction (GEJ) is gaining more popularity in the developed world mainly because of its better cosmetic results, lesser pain and lesser postoperative stay without compromising the radicality of the cancer surgery...

  • Safety, efficacy, and long-term outcomes for endoscopic submucosal dissection of early esophagogastric junction cancer. Omae, Masami; Fujisaki, Junko; Horiuchi, Yusuke; Yoshizawa, Natsuko; Matsuo, Yasumasa; Kubota, Manabu; Suganuma, Takanori; Okada, Kazuhisa; Ishiyama, Akiyoshi; Hirasawa, Toshiaki; Yamamoto, Yorimasa; Tsuchida, Tomohiro; Hoshino, Etsuo; Igarashi, Masahiro // Gastric Cancer;Apr2013, Vol. 16 Issue 2, p147 

    Background: Early esophagogastric junction (EGJ) cancer is currently being treated in the same way as early gastric cancer, by endoscopic submucosal dissection (ESD), but long-term outcomes are still unknown. Our aim was to retrospectively evaluate the safety and efficacy of ESD in treating...

  • "Damage Control" Esophagogastrectomy in Case of Perforated and Bleeding Gastroesophageal Cancer. Moldovan, Bogdan; Pocreajă, Dumitru; Teodorescu, Dan; Coroş, Marius; Sârbu, Viorica; Baila, Lucian; Tanlău, Marcel; Grusea, Dragos; Pescaru, Florentina; Moldovan, Andreea; Biriş, Laura // Jurnalul de Chirurgie;2014, Vol. 10 Issue 2, p159 

    Introduction: The term "damage control surgery" or "laparotomie écourtée" is not a new concept, but a recent paradigm in the surgery of abdominal trauma, when the ability to maintain homeostasis is impaired due to severe hemorrhage. It can be defined as a surgical method that prevents the...

  • Phase I/II trial of triplet regimen with docetaxel, oxaliplatin and capecitabine in advanced gastric and gastroesophageal cancers. Eswaran, Prasad; Kannan, Kalaichelvi; Narasimhan, Srinivasan Lakshmi; Balaji; Kumar, Suresh; Mavalavan, Durai // Clinical Cancer Investigation Journal;Jul-Aug2015, Vol. 4 Issue 4, p504 

    Background: Advanced and metastatic gastric cancers present at late stages and have very dismal prognosis. Many modifications have been tried for improving the outcome. Docetaxel, cisplatin and fluorouracil/epirubicin, cisplatin and fluorouracil regimen have been established as a standard...

  • Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). C Pinto; F Di Fabio; S Siena; S Cascinu; FL Rojas Llimpe; C Ceccarelli; V Mutri; L Giannetta; S Giaquinta; C Funaioli; R Berardi; C Longobardi; E Piana; AA Martoni // Annals of Oncology;Mar2007, Vol. 18 Issue 3, p510 

    Background: The purpose of this phase II study was to evaluate the efficacy and safety of cetuximab combined with FOLFIRI as a first-line treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.Patients and methods: Untreated patients with confirmed advanced gastric or...

  • Results of combination chemotherapy and radiation therapy in non-metastatic gastric cancer in Yazd--Iran. Akhavan, A.; Binesh, F.; Seifaddiny, A. // Indian Journal of Cancer;Jan-Mar2015, Vol. 52 Issue 1, p40 

    Background: Gastric cancer is the first cause of cancer death in Iran. Most of the patients are diagnosed in advanced stages and survival rate is low. The aim of this study was to evaluate the survival rate of patients with gastric and gastroesophageal junction adenocarcinoma...

  • Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer. Lorenzen, S; Pauligk, C; Homann, N; Schmalenberg, H; Jäger, E; Al-Batran, S-E // British Journal of Cancer;2/12/2013, Vol. 108 Issue 3, p519 

    Background:The aim of this exploratory subgroup analysis of the fluorouracil, oxaliplatin, docetaxel (FLOT)65+ trial was to determine tolerability and feasibility of perioperative chemotherapy in elderly, potentially operable esophagogastric cancer patients.Methods:Patients aged 65 with...

  • Bevacizumab/capecitabine/docetaxel.  // Reactions Weekly;Mar2014, Vol. 1491 Issue 1, p12 

    An abstract of the article "Durable, complete remission with bevacizumab-based chemotherapy in a patient with metastatic gastroesophageal junction cancer," by M. H. Rashid and colleagues is presented.

  • Trastuzumab.  // Reactions Weekly;Aug2014, Vol. 1512 Issue 1, p36 

    The article presents a case study of a patient who was admitted to hospital for myocardial infarction after being treated for HER-2 gastric and gastroesophageal junction (GE) cancer.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics